Inflammatory demyelinating diseases of the central nervous system

Inflammatory demyelinating diseases (IDDs), sometimes called Idiopathic (IIDDs) because the unknown etiology of some of them, and sometimes known as borderline forms of multiple sclerosis,[1] is a collection of multiple sclerosis variants, sometimes considered different diseases,[2][3] but considered by others to form a spectrum differing only in terms of chronicity, severity, and clinical course.[4][5]

Multiple Sclerosis could be considered among the acquired demyelinating syndromes with a multiphasic instead of monophasic behaviour.[6]

Diseases included in this category

The list of these diseases depends of the author, but usually are included:

Some inflammatory conditions are associated with the presence of the scleroses.[23] Optic neuritis (monophasic and recurrent) and Transverse myelitis (monophasic and recurrent)

As MS is an active field for research, the list is not closed or definitive. For example, some diseases like Susac's syndrome (MS has an important vascular component[24]), leukoaraiosis, myalgic encephalomyelitis (aka chronic fatigue syndrome)[25] or autoimmune variants of peripheral neuropathies like Guillain-Barré syndrome or progressive inflammatory neuropathy could be included assuming the autoimmune model. Also Leukodystrophy (which see) and its sub-conditions: Adrenoleukodystrophy and Adrenomyeloneuropathy could be in the list. Venous induced demyelination has also been proposed as a hypothetical MS variant produced by CCSVI. Recent research has identified some possible new variants, like the possibility to separate primary progressive MS, PPMS, after recent findings seem to point that it is pathologically a very different disease.[26][27] Also a KIR4.1 multiple sclerosis variant was reported in 2012[28] and later reported again,[29] which could be considered a different disease (as Devic disease did before), and can represent up to a 47% of the MS cases. Finally, there exist some reports of an aquaporine-related multiple sclerosis, related to vegetal aquaporine proteins.[30]

Identified causes

Though for the most of the cases these diseases are still idiopathic, recent researchs have found the causes for some of them, making them not idiopathic anymore. The two identified auto-antibodies so far are the following[31]

anti-AQP4 spectrum

Originally found in neuromyelitis optica, this autoantibody has been associated with other conditions. Its current spectrum is as following:

anti-MOG spectrum

The presence of anti-MOG autoantibodies has been associated with the following conditions[35]

The anti-mog spectrum in children is equally variated: Out of a sample of 41 children with MOG-antibodies 29 had clinical NMOSD (17 relapsing), 8 had ADEM (4 relapsing with ADEM-ON), 3 had a single clinical event CIS, and 1 had a relapsing tumefactive disorder. Longitudinal myelitis was evident on MRI in 76[percnt]. It has also been noted that percentage of children with anti-mog antibodies respect a demyelinating sample is higher than for adults[39]

Clinical situations inside standard MS

Also inside standard MS different clinical courses can be separated.

Primary progressive variant

Some authors also think that primary progressive multiple sclerosis should be considered a different entity from standard MS (MS with two phases, recurrent-recidivant and secondary progressive, RRMS+SPMS).[40][41] Others maintain the opposite.[42] In any case, the lesions in PPMS can be diffused instead of the normal focal ones,[43] and are different under MR spectroscopy.[44][45] RRMS and PPMS patients also show differences on the retinal layers yields examined under OCT.[46]

Some authors have proposed a dual classification of PPMS, according to the shape of edges of the scars, in MS-like and ADEM-like[47] Proteomic analysis have shown that two proteins, Secretogranin II and Protein 7B2, in CSF can be used to separate RRMS from PPMS[48]

Recently, the hypothesis of PPMS being apart from RRMS/SPMS is taken further credibility due that it was shown that CSF from PPMS patients can carry the disease to other animals, producing neurodegeneration in mice[26]

It has also been proposed than PPMS could be heterogeneous. An antibody (immunoglobulin M) oligoclonal bands would be the biomarker for an specific kind of PPMS, in a similar way to what AQP4-IgG is for NMO.[49]

Preclinical MS: CIS and CDMS

The first manifestation of MS is the so-called Clinically isolated syndrome, or CIS, which is the first isolated attack. The current diagnosis criteria for MS does not allow doctors to give an MS diagnosis until a second attack takes place. Therefore the concept of "clinical MS", for an MS that can be diagnosed, has been developed. Until MS diagnosis has been established, nobody can tell whether the disease dealing with is MS.

Cases of MS before the CIS are sometimes found during other neurological inspections and are referred to as subclinical MS.[50] Preclinical MS refers to cases after the CIS but before the confirming second attack.[51] After the second confirming attack the situation is referred to as CDMS (clinically defined multiple sclerosis).[52]

RIS, subclinical and silent MS

Silent MS has been found in autopsies before the existence of MRI[53] showing that the so called "clinical definitions" cannot be applied to around 25% of the MS cases.[54] Currently a distinction is made between "silent" and subclinical.

In absence of attacks, sometimes a radiological finding suggestive of demyelination can be used to establish a pre-diagnosis of MS. This is often named "Radiologically Isolated Syndrome" (RIS). Cases before the first attack or CIS are subclinical in the sense that they do not produce clinical situations.

If a second radiological event appears without clinical consequences, the clinical situation is named "Silent MS" (Okuda criteria).[55]

It has been noted that some aspects of the MS underlying condition are present in otherwise healthy MS patients' relatives,[56] suggesting a wider scope for the "silent MS" term.

In these cases Interleukin-8 is a risk for clinical conversion.[57] It has also been proposed that always exists a subclinical phase in the beginning of every MS case, during which the permeability of the BBB can be used for diagnosis[58]

Aggressive multiple sclerosis

Relapsing-Remitting MS is considered aggressive when the frequency of exacerbations is not less than 3 during 2 years. Special treatment is often considered for this subtype.[59] According to these definition aggressive MS would be a subtype of RRMS. Other authors disagree and define aggressive MS by the accumulation of dissability, considering it as a rapidly disabling disease course[60]

Pediatric and pubertal MS

MS cases are rare before puberty, but they can happen. Whether they constitute a separate disease is still an open subject. Anyway, even this pubertal MS could be more than one disease, because early-onset and late-onset have different demyelination patterns[61]

Controversy for the definition

Clinical vs. pathological definitions

There is no agreement if MS should refer to a clinical course or to a pathological condition. Even assuming a pathological definition it is not clear if MS should refer to the presence of scars in CNS tissue or to the underlying condition that produces them, characterized by some yet unknown biomarkers.

Probably the most implicitly used definition is pathological, and can be found in the McDonald criteria proposal. This author state that "The focus remains on the objective demonstration of dissemination of lesions in both time and space". Therefore they point out to a pathological underlying definition. Nevertheless, they say "MS is a clinical entity and therefore should be diagnosized with clinical and paraclinical criteria".[62] Currently the McDonald criteria are considered the clinical case definition of MS.

Given the non-specificity of the McDonald underlying definition, based on dissemination in time and space regardless of the lesions nature, other authors consider that a more accurate pathological definition should be used.[63] According to Hans Lassmann, an improved pathological definition should be preferred because clinical definitions have problems with differential diagnosis.[64] Of course, using a pathological definition would not prevent performing clinical diagnosis, but would require to calibrate any diagnosis criteria against it.

McDonald et al. do not agree with this, and they remark on the clinical character of MS. They state that "Whereas it might be said that the only proved diagnosis of MS can be made upon autopsy, or occasionally upon biopsy, where lesions typical of MS can be directly detected through standard histopathological techniques, MS is essentially a clinical problem and can be diagnosed using clinical and paraclinical criteria""[62]

At this moment, both definitions are currently used by each of their supporters and the relationship among them is not well documented.

Current definitions

The list of diseases included in the MS-spectrum is not closed because no formal definition of MS is normally given. For example, the World Health Organization does not give any explicit definition with ICD-10 MS entry . In ICD-9 it used to say "chronic disease characterized by presence of numerous areas of demyelination in the central nervous system with symptoms such as weakness, incoordination, paresthesis, and speech disturbances".

The Unified Medical Language System also gives very loose definitions of MS . The Medline medical dictionary defines it as "a demyelinating disease marked by patches of hardened tissue in the brain or the spinal cord and associated especially with partial or complete paralysis and jerking muscle tremor" . It uses the anatomical hallmark of the lesions, but also imposes the existence of clinical problems (paralysis and jerking muscle tremor).

Assuming a definition as weak as the previous ones, several diseases could be included inside the MS-spectrum. Most authors use a definition for MS based in the dissemination of the lesions in time (DIT) and space (DIS)[65] These definitions refer to the lesions and their location, but not to the nature of the lesions and this kind of definition is potentially heterogeneous.

Besides while some pathologysts consider that MS is the presence of demyelinated and disseminated scars in the CNS tissue,[63] others consider that MS is the unknown underlying condition that produces those scars.[66] These subtle differences can affect statistics and the reader should be aware of the definition in which each paper is based.

See also

References

  1. ↑ Fontaine B (2001). "[Borderline forms of multiple sclerosis]". Rev. Neurol. (Paris) (in French) 157 (8-9 Pt 2): 929–34. PMID 11787357.
  2. ↑ Wingerchuk DM, Lucchinetti CF (2007). "Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis". Curr. Opin. Neurol. 20 (3): 343–50. doi:10.1097/WCO.0b013e3280be58d8. PMID 17495631.
  3. ↑ Poser CM, Brinar VV (October 2007). "Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review". Acta Neurol. Scand. 116 (4): 201–6. doi:10.1111/j.1600-0404.2007.00902.x. PMID 17824894.
  4. ↑ Weinshenker B, Miller D (1998). "Multiple sclerosis: one disease or many?". In Thompson AB, Siva A, Kesselring J. Frontiers in Multiple Sclerosis (2nd ed.). London: Taylor & Francis Group. pp. 37–46. ISBN 1-85317-506-4.
  5. ↑ Hartung HP, Grossman RI (May 2001). "ADEM: distinct disease or part of the MS spectrum?". Neurology 56 (10): 1257–60. doi:10.1212/WNL.56.10.1257. PMID 11376169.
  6. ↑ Quintana FJ, Patel B, Yeste A, Nyirenda M, Kenison J, Rahbari R, Fetco D, Hussain M, O'Mahony J, Magalhaes S, McGowan M, Johnson T, Rajasekharan S, Narayanan S, Arnold DL, Weiner HL, Banwell B, Bar-Or A (2014). "Epitope spreading as an early pathogenic event in pediatric multiple sclerosis". Neurology 83 (24): 2219–26. doi:10.1212/WNL.0000000000001066. PMID 25381299.
  7. ↑ Bruno Brochet, Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases, Springer international, Switzerland 2015, ISBN 3319184644, 9783319184647
  8. ↑ Kalanie H, Kholghie Y, Shamsai GR, Ghorbani M (October 2008). "Opticospinal multiple sclerosis in Iran". J. Neurol. Sci. 276 (1-2): 130–2. doi:10.1016/j.jns.2008.09.038. PMID 18962726. Check date values in: |year= / |date= mismatch (help)
  9. ↑ Kira J (October 2008). "Neuromyelitis optica and asian phenotype of multiple sclerosis". Ann. N. Y. Acad. Sci. 1142 (1): 58–71. Bibcode:2008NYASA1142...58K. doi:10.1196/annals.1444.002. PMID 18990121.
  10. ↑ Matsushita T, Isobe N, Matsuoka T, Shi N, Kawano Y, Wu XM, Yoshiura T, Nakao Y, Ishizu T, Kira JI (2009). "Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese". Mult. Scler. 15 (7): 834–47. doi:10.1177/1352458509104595. PMID 19465451.
  11. ↑ Weinshenker Brian G (2014). "The two faces of neuromyelitis optica". Neurology 82 (6): 466–467. doi:10.1212/WNL.0000000000000114.
  12. ↑ Pröbstel AK et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015 Mar 8;12(1):46.
  13. ↑ Spadaro Melania; et al. (2015). "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational Neurology 2 (3): 295–301. doi:10.1002/acn3.164.
  14. ↑ Ian Rossman. An 8 Year Old Girl with Chronic Inflammatory Optic Neuritis (CRION): the Youngest Reported Case to Date, Neurology April 6, 2015 vol. 84 no. 14 Supplement P7.015
  15. ↑ Garrido C, Levy-Gomes A, Teixeira J, Temudo T (2004). "[Schilder's disease: two new cases and a review of the literature]". Rev Neurol (in Spanish) 39 (8): 734–8. PMID 15514902.
  16. ↑ Afifi AK, Bell WE, Menezes AH, Moore SA (1994). "Myelinoclastic diffuse sclerosis (Schilder's disease): report of a case and review of the literature". J. Child Neurol. 9 (4): 398–403. doi:10.1177/088307389400900412. PMID 7822732.
  17. ↑ Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W (July 2008). "Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis". Brain 131 (Pt 7): 1759–75. doi:10.1093/brain/awn098. PMC 2442427. PMID 18535080.
  18. ↑ Given CA, Stevens BS, Lee C (1 January 2004). "The MRI appearance of tumefactive demyelinating lesions". AJR Am J Roentgenol 182 (1): 195–9. doi:10.2214/ajr.182.1.1820195. PMID 14684539.
  19. ↑ Schmalstieg WF, Keegan BM, Weinshenker BG (Feb 2012). "Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion". Neurology 78 (8): 540–4. doi:10.1212/WNL.0b013e318247cc8c. PMID 22323754.
  20. ↑ Lattanzi S (2012). "Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion". Neurology 79 (4): 393; author reply 393. doi:10.1212/01.wnl.0000418061.10382.f7. PMID 22826546.
  21. ↑ Ayrignac X, Carra-Dalliere C, Homeyer P, Labauge P (2013). "Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. A new entity?". Acta Neurol Belg 113 (4): 533–4. doi:10.1007/s13760-013-0182-x. PMID 23358965.
  22. ↑ Jiménez Arango JA, Uribe Uribe CS, Toro González G (2013). "Lesser-known myelin-related disorders: Focal tumour-like demyelinating lesions". Neurologia 30: 97–105. doi:10.1016/j.nrl.2013.06.004. PMID 24094691.
  23. ↑ O'Connor P, Marriott J (2010). "Differential Diagnosis and Diagnostic Criteria for Multiple Sclerosis: Application and Pitfalls" (PDF). In Hohlfeld R, Lucchinetti CF. Multiple sclerosis 3 (1st ed.). Philadelphia: Saunders Elsevier. ISBN 978-1-4160-6068-0.
  24. ↑ Minagar A, Jy W, Jimenez JJ, Alexander JS (2006). "Multiple sclerosis as a vascular disease". Neurol. Res. 28 (3): 230–5. doi:10.1179/016164106X98080. PMID 16687046.
  25. ↑ "Chronic Fatigue Syndrome - Symptoms, Diagnosis, Treatment of Chronic Fatigue Syndrome". Health Information. New York Times. The following test results... are seen consistently...: Brain MRI showing swelling in the brain or destruction of part of the nerve cells (demyelination)
  26. 1 2 Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA (2014). "Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice". Exp. Neurol. 261: 620–32. doi:10.1016/j.expneurol.2014.07.020. PMID 25111532.
  27. ↑ Ulloa Bianca, Alahiri Marwan, Liu Ying, Sadiq Saud (2015). "Cerebrospinal Fluid Haptoglobin (Hp) Levels are elevated in MS patients with progressive disease". Neurology 84 (14): 213.
  28. ↑ Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B (2012). "Potassium channel KIR4.1 as an immune target in multiple sclerosis". N. Engl. J. Med. 367 (2): 115–23. doi:10.1056/NEJMoa1110740. PMID 22784115.
  29. ↑ Schneider R (2013). "Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis". Front Neurol 4: 125. doi:10.3389/fneur.2013.00125. PMC 3759297. PMID 24032025.
  30. ↑ Vojdani A, Mukherjee PS, Berookhim J, Kharrazian D (2015). "Detection of antibodies against human and plant aquaporins in patients with multiple sclerosis". Research abs 2: 1378. doi:10.13070/ev.en.2.1378.
  31. ↑ Kazutoshi Sato Douglas; et al. (Feb 2014). "Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders". Neurology 82 (6): 474–481. doi:10.1212/WNL.0000000000000101.
  32. ↑ Li Y, Xie P, Lv F, et al. (2008). "Brain magnetic resonance imaging abnormalities in neuromyelitis optica". Acta Neurol. Scand. 0 (4): 218–25. doi:10.1111/j.1600-0404.2008.01012.x. PMID 18384459.
  33. ↑ Wingerchuk, Dean (2006). "Neuromyelitis Optica (Devic's Syndrome)" (PDF). 2006 Rare Neuroimmunologic Disorders Symposium. Retrieved 2007-01-05.
  34. ↑ Ken Ikeda et al. Repeated Non-enhancing Tumefactive Lesions in a Patient with a Neuromyelitis Optica Spectrum Disorder. Internal Medicine Vol. 50 (2011) No. 9 P 1061-1064, 2011/05/01, http://doi.org/10.2169/internalmedicine.50.4295
  35. 1 2 3 Reindl M, Di Pauli F, Rostásy K, Berger T (Aug 2013). "The spectrum of MOG autoantibody-associated demyelinating diseases". Nat Rev Neurol 9 (8): 455–61. doi:10.1038/nrneurol.2013.118. PMID 23797245.
  36. ↑ Spadaro Melania; et al. (2015). "Histopathology and clinical course of MOG-antibody-associated encephalomyelitis". Annals of Clinical and Translational Neurology 2 (3): 295–301. doi:10.1002/acn3.164.
  37. ↑ M. Baumann, E.M. Hennes, K. Schanda, M. Karenfort, B. Bajer-Kornek, K. Diepold, B. Fiedler, I. Marquardt, J. Strautmanis, S. Vieker, M. Reindl, K. Rostásy. Clinical characteristics and neuroradiological findings in children with multiphasic demyelinating encephalomyelitis and MOG antibodies. European Journal of Paediatric Neurology, Volume 19, Supplement 1, May 2015, Pages S21, Abstracts of the 11th EPNS Congress. 22 May 2015. doi:10.1016/S1090-3798(15)30066-0
  38. ↑ Chalmoukou K; et al. (2015). "Recurrent Optic Neuritis (rON) is characterised by Anti-MOG Antibodies: A follow-up study". Neurology 84 (14 Suppl P5): 274.
  39. ↑ Silvia Tenembaum et al. Spectrum of MOG Autoantibody-Associated Inflammatory Diseases in Pediatric Patients, Neurology 2015; vol. 84 no. 14 Supplement I4-3A
  40. ↑ Vukusic S, Confavreux C (2003). "Primary and secondary progressive multiple sclerosis". J. Neurol. Sci. 206 (2): 153–5. doi:10.1016/S0022-510X(02)00427-6. PMID 12559503.
  41. ↑ Dressel A, Kolb AK, Elitok E, Bitsch A, Bogumil T, Kitze B, Tumani H, Weber F (2006). "Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis". Acta Neurol. Scand. 114 (6): 368–73. doi:10.1111/j.1600-0404.2006.00700.x. PMID 17083335.
  42. ↑ Ebers GC (2004). "Natural history of primary progressive multiple sclerosis". Mult. Scler. 10. 10 Suppl 1 (3): S8–13; discussion S13–5. doi:10.1191/1352458504ms1025oa. PMID 15218804.
  43. ↑ Zwemmer JN, Bot JC, Jelles B, Barkhof F, Polman CH (April 2008). "At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only". Mult. Scler. 14 (3): 428–30. doi:10.1177/1352458507084591. PMID 18208890.
  44. ↑ Rahimian N, Saligheh Rad H, Firouznia K, Ebrahimzadeh SA, Meysamie A, Vafaiean H, Harirchian MH (September 2013). "Magnetic resonance spectroscopic findings of chronic lesions in two subtypes of multiple sclerosis: primary progressive versus relapsing remitting". Iran J Radiol 10 (3): 128–32. doi:10.5812/iranjradiol.11336 (inactive 2015-01-14). PMC 3857974. PMID 24348597.
  45. ↑ Reinke SN, Broadhurst DL, Sykes BD, Baker GB, Catz I, Warren KG, Power C (2014). "Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis". Mult. Scler. 20 (10): 1396–400. doi:10.1177/1352458513516528. PMID 24468817.
  46. ↑ Balk L, Tewarie P, Killestein J, Polman C, Uitdehaag B, Petzold A (2014). "Disease course heterogeneity and OCT in multiple sclerosis". Mult. Scler. 20 (9): 1198–1206. doi:10.1177/1352458513518626. PMID 24402036.
  47. ↑ Poser CM, Brinar VV (2004). "The nature of multiple sclerosis". Clin Neurol Neurosurg 106 (3): 159–71. doi:10.1016/j.clineuro.2004.02.005. PMID 15177764.
  48. ↑ Liguori M, Qualtieri A, Tortorella C, Direnzo V, Bagalà A, et al. (2014). "Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration". PLoS ONE 9 (8): e103984. doi:10.1371/journal.pone.0103984. PMID 25098164.
  49. ↑ Villar LM; et al. (Aug 2014). "Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis". Ann Neurol 76 (2): 231–40. doi:10.1002/ana.24190.
  50. ↑ Hakiki B, Goretti B, Portaccio E, Zipoli V, Amato MP (2008). "'Subclinical MS': follow-up of four cases". Eur. J. Neurol. 15 (8): 858–61. doi:10.1111/j.1468-1331.2008.02155.x. PMID 18507677.
  51. ↑ Lebrun C, Bensa C, Debouverie M, De Seze J, Wiertlievski S, Brochet B, Clavelou P, Brassat D, Labauge P, Roullet E (2008). "Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile". J. Neurol. Neurosurg. Psychiatr. 79 (2): 195–8. doi:10.1136/jnnp.2006.108274. PMID 18202208.
  52. ↑ Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Mirabella M, Tonali PA, Batocchi AP (December 2008). "The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis". J. Neuroimmunol. 205 (1-2): 126–34. doi:10.1016/j.jneuroim.2008.09.003. PMID 18926576.
  53. ↑ Mackay Roland P., Hirano Asao (1967). "Report of two clinically silent cases discovered at autopsy". Arch Neurol 17 (6): 588–600. doi:10.1001/archneur.1967.00470300030007.
  54. ↑ Engell T (May 1989). "A clinical patho-anatomical study of clinically silent multiple sclerosis". Acta Neurol Scand 79 (5): 428–30. doi:10.1111/j.1600-0404.1989.tb03811.x. PMID 2741673.
  55. ↑ Gabelic T, Ramasamy DP, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Hojnacki D, Ramanathan M, Zivadinov R (2014). "Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis". AJNR Am J Neuroradiol 35 (1): 106–12. doi:10.3174/ajnr.A3653. PMID 23886745. Lay summary – msdiscovery.org.
  56. ↑ Gabelic T, Weinstock-Guttman B, Melia R, Lincoff N, Masud MW, Kennedy C, Brinar V, Ramasamy DP, Carl E, Bergsland N, Ramanathan M, Zivadinov R (2013). "Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients". Clin Neurol Neurosurg. 115 Suppl 1: S49–54. doi:10.1016/j.clineuro.2013.09.021. PMID 24321155.
  57. ↑ Rossi S; et al. (2015). "Subclinical central inflammation is risk for RIS and CIS conversion to MS.". Mult Scler. doi:10.1177/1352458514564482. PMID 25583841.
  58. ↑ Cramer; et al. (2015). "Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis". Brain 138: 2571–83. doi:10.1093/brain/awv203. PMID 26187333.
  59. ↑ Sazonov DV, Malkova NA, Bulatova EV, Riabukhina OV (2009). "[Combined therapy of aggressive remitted multiple sclerosis with mitoxantrone in combination with copaxone]". Zh Nevrol Psikhiatr Im S S Korsakova 109 (12): 76–9. PMID 20037526.
  60. ↑ Rush, MacLean, Freedman. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015 Jun 2. doi: 10.1038/nrneurol.2015.85. PMID 26032396
  61. ↑ Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E (September 2008). "Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?". Neurology 71 (14): 1090–3. doi:10.1212/01.wnl.0000326896.66714.ae. PMID 18824673.
  62. 1 2 McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001). "Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis" (PDF). Ann. Neurol. 50 (1): 121–7. doi:10.1002/ana.1032. PMID 11456302.
  63. 1 2 Dutta R, Trapp BD (2006). "[Pathology and definition of multiple sclerosis]". Rev Prat (in French) 56 (12): 1293–8. PMID 16948216.
  64. ↑ Lassmann H (2010). "Acute disseminated encephalomyelitis and multiple sclerosis". Brain 133 (Pt 2): 317–9. doi:10.1093/brain/awp342. PMID 20129937.
  65. ↑ Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008). "Differential diagnosis of suspected multiple sclerosis: a consensus approach". Mult. Scler. 14 (9): 1157–74. doi:10.1177/1352458508096878. PMC 2850590. PMID 18805839.
  66. ↑ Lassmann H (2007). "Multiple sclerosis: is there neurodegeneration independent from inflammation?". J. Neurol. Sci. 259 (1-2): 3–6. doi:10.1016/j.jns.2006.08.016. PMID 17367814.
This article is issued from Wikipedia - version of the Monday, February 15, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.